Gestational trophoblastic neoplasia with retroperitoneal metastases: A fatal complication by Thomakos, Nikolaos et al.
CASE REPORT Open Access
Gestational trophoblastic neoplasia with
retroperitoneal metastases: A fatal complication
Nikolaos Thomakos
1, Alexandros Rodolakis
1, Panayiotis Belitsos
1, Flora Zagouri
2, Ioannis Chatzinikolaou
2,
Athanassios-Meletios Dimopoulos
2, Christos A Papadimitriou
2*, Aris Antsaklis
1
Abstract
Background: Gestational Trophoblastic Neoplasia (GTN) is a pathologic entity that can affect any pregnancy and
develop long after the termination of the pregnancy. Its course can be complicated by metastases to distant sites
such as the lung, brain, liver, kidney and vagina. The therapeutic approach of this condition includes both surgical
intervention and chemotherapy. The prognosis depends on many prognostic factors that determine the stage of
the disease.
Case Report: We present a woman with GTN and retroperitoneal metastatic disease who came to our department
and was diagnosed as having high risk metastatic GTN. Accordingly she received chemotherapy as primary
treatment but unfortunately developed massive bleeding after the first course of chemotherapy, was operated in
an attempt to control bleeding but finally succumbed.
Conclusion: This case demonstrates that GTN, while usually curable, can be a deadly disease requiring improved
diagnostic, treatment modalities and chemotherapeutic agents. The gynaecologist should be aware of all possible
metastatic sites of GTN and the patient immediately referred to a specialist center for further assessment and
treatment.
Introduction
Gestational Trophoblastic Neoplasia (GTN) refers to a
pathologic condition that is characterized by aggressive
invasion of the endometrium and myometrium by tro-
phoblastic cells and is divided to four different pathologic
entities: invasive mole, gestational choriocarcinoma, pla-
cental site trophoblastic tumour and epithelioid tropho-
blastic tumour [1]. GTN typically develops with or
follows some form of pregnancy, but occasionally an
antecedent gestation cannot be confirmed with certainty.
Most cases follow a hydatidiform mole. Rarely, GTN
develops after a live birth, miscarriage, or termination [2].
Metastases in GTN develop in about 4% after evacua-
tion of a complete mole [3] but are more often seen
when GTN develops after non-molar pregnancies. High
propensity of distant metastases characterizes gestational
choriocarcinoma which develops in approximately 1 in
30,000 non-molar pregnancies [3-5]. Two thirds of such
cases follow term pregnancies, and a third develops after
a spontaneous abortion or pregnancy termination [3].
Choriocarcinoma should be suspected in any woman of
reproductive age with metastatic disease from an
unknown primary [4,5]. Moreover, it may be suspected
in any abnormal bleeding for more than 6 weeks follow-
ing a pregnancy; in this case human Chorionic Gonado-
trophin (hCG) testing is indicated to exclude a new
pregnancy or GTN [4,5]. Gestational choriocarcinomas
initially invade the endometrium and myometrium
although blood-borne systemic metastases tend to
develop early during the course of the disease [6]. This
can be explained by the great vascularity of trophoblas-
tic tumours which causes them to bleed profusely [6].
The diagnosis of choriocarcinoma is often delayed due
to subtle signs and symptoms of disease in patients with
an antecedent normal pregnancy. Therefore choriocarci-
noma has a significantly higher mortality rate than GTN
following non-molar abortions; this rate reaches up to
14% [4,7,8]. * Correspondence: chr_papadim@yahoo.gr
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metastases and uncontrollable bleeding after the first
cycle of chemotherapy.
Case Report
A G3P1 39-year-old woman of Asian origin complaining
of diffuse abdominal pain and vaginal bleeding was
referred to our department with ultrasound findings
compatible with molar pregnancy. Obstetrical history
included Caesarean Section 4 years ago and a termina-
tion of pregnancy within the last six months. Her last
menstrual period was 14 weeks before admission.
Physical examination revealed uterine size that corre-
sponded to 18 weeks pregnancy and the content was
compatible with molar pregnancy (Figure 1). The
laboratory workup revealed profound anaemia (Haema-
tocrit 26%) and b-hHG >22.500. The Computerised
Tomography of the abdomen confirmed the findings of
the ultrasound scan while the chest CT showed multiple
nodular lesions in both lung fields (Figure 2, 3). The
patient was classified as high risk (total score 9) accord-
ing to the WHO Prognostic Scoring System for Gesta-
tional Trophoblastic Disease (GTD).
She initially underwent dilatation and curettage which
was incomplete and had to be repeated after 2 days.
Histology showed complete molar pregnancy. According
to FIGO staging system the patient was stage III high-
risk invasive GTD; therefore chemotherapy was sched-
uled. The chemotherapy regimen included Bleomycin,
Etoposide and CDDP given for 4 cycles. Each cycle
included 3 days Bleomycin 15 mg/day, 3 days of Etopo-
side 120 mg/m2 and 2 days of CDDP 50 mg/m2.
One day after the first cycle of chemotherapy she
started to complain of diffuse abdominal pain and
within 10-15 minutes she lost consciousness and had a
cardiac arrest but she was successfully resuscitated and
because of the continuous drop in the Haematocrit and
abdominal paracentesis positive for blood, it was decided
to proceed with explorative laparotomy.
During laparotomy diffuse retroperitoneal bleeding
was encountered from multiple microscopic amd
macroscopic sites. A general surgeon was called to
assist the operating team. Initially the gynecological
team tried to put some sutures for hemostasis in
macroscopically bleeding sites, especially in the sub-
diaphragmaic areas. In an attempt to control bleeding
splenectomy was performed. Hemorrhage control was
impossible and the retroperitoneal space was tampo-
naded in order to stabilize the patient and re-operate
her after 48 hours. The patient was then transferred to
the ICU where she continued to bleed. She received a
total of 26 concentrated red blood cell units as well as
fresh frozen plasma, concentrated coagulation factors,
colloids and even somatostatin in order to stabilize or
reverse her deteriorating condition. Unfortunately she
finally developed DIC due to uncontrollable bleeding
and died after 3 days.
Discussion
Choriocarcinomas originating from complete molar
gestations comprise most cases of metastatic GTN [2].
Four to five percent of complete moles develop meta-
static choriocarcinoma after evacuation and chemother-
apy is indicated whenever choriocarcinoma is diagnosed
histological [2]. Although many patients are largely
asymptomatic, metastatic GTN is highly vascular and
prone to severe haemorrhage either spontaneously or
during biopsy. The most common sites of metastases
are the lungs (80%), vagina (30%), pelvis (20%), liver
(10%), and brain (10%) [9].
Figure 1 Ultrasound showing uterus content compatible with molar pregnancy.
Thomakos et al. World Journal of Surgical Oncology 2010, 8:114
http://www.wjso.com/content/8/1/114
Page 2 of 6As concerns the clinical manifestations, menorrhagia
is the most common presenting symptom. Patients with
pulmonary metastases typically have asymptomatic
lesions identified on routine chest radiograph and infre-
quently present with cough, dyspnoea, haemoptysis, or
signs of pulmonary hypertension [10]. Hepatic or cere-
bral involvement is encountered almost exclusively in
patients who have had an antecedent non-molar preg-
nancy and a protracted delay in tumour diagnosis [11].
These women may present with associated haemorrha-
gic events. Virtually all patients with hepatic or cerebral
metastases have concurrent pulmonary or vaginal invol-
vement or both [9]. Great caution is used in attempting
excision of any metastatic disease site due to the risk of
profuse haemorrhage [2,9,12]; therefore metastasis
should generally not be resected. Thus, this practice is
almost uniformly avoided except in extenuating circum-
stances of life-threatening brain stem herniation or che-
motherapy-resistant disease.
Patients with GTN should undergo a thorough pretreat-
ment assessment to determine the extent of disease. The
initial evaluation includes a pelvic examination, chest
radiograph, and ultrasound or abdominal-pelvic CT scan
[13,14]. Although the chest radiographs are considered
adequate for lung metastases detection, frequently lesions
can be missed on conventional radiographs and a CT scan
is recommended to confirm pulmonary metastatic disease.
In addition, positron-emission tomography/computed
Figure 2 Abdominal CT showing occupation of the uterus by the trophoblastic tissue.
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occult choriocarcinoma when conventional imaging fails
to identify metastatic disease [15]. Other diagnostic work-
ups should include liver function tests.
World Health Organization (WHO) modified the
prognostic scoring system in an attempt to distinguish
patients at low risk for therapeutic failure from those at
high risk. Women with high risk scores are more likely
to have tumors that are resistant to single-agent che-
motherapy. They are therefore treated initially with
combination chemotherapy.
Treatment is initiated primarily with chemotherapeutic
agents [9]. Gordon et al found that patients with score of
at least 8 required multiagent chemotherapy [16]. Bag-
s h a w ee ta li n1 9 8 9f o u n dt h a tm e d i u ma n dh i g hr i s k
patients (score 5 or more) should also receive multiagent
chemotherapy [17]. Chemotherapy for High-Risk GTN
includes Etoposide, methotrexate, and dactinomycin
alternating with cyclophosphamide and vincristine
(EMA/CO) which is a well-tolerated and highly effective
(83% survival rate and cure rate as high as 100%) regimen
for high-risk GTN that should be considered the primary
treatment in most circumstances. The regimen is
repeated every 14 days [9].
EMA-CO remains the preferred chemotherapy for
management [18-22], however other regimens like
Figure 3 Chest CT showing the multiple metastases of the trophoblastic disease.
Thomakos et al. World Journal of Surgical Oncology 2010, 8:114
http://www.wjso.com/content/8/1/114
Page 4 of 6EMA-EP (etoposide, ethotrexate, actinomycin and cis-
platinum), PVB (cisplatin, vinblastine and bleomycin),
and BEP (bleomycin, etoposide and cisplatin) are widely
used especially as second-line therapy in women who
experienced resistance to primary chemotherapy
[18-22]. Moreover, vincristine/actinomycin D/cyclopho-
sphamide (VAC) or vincristine/iphosphamide/cisplatin
(VIP) have been reported to be used as third line treat-
ment [19,22]. In our patient we preferred to use BEP
regimen; a well tolerated combination with approved
efficacy [18-22]. Optimization of treatment strategies for
those who develop drug resistance remains a key chal-
lenge; therefore different regimens and multiple combi-
nations are widely used [18,19,22].
Response rates are comparable whether patients are
treated primarily or after failure of single-agent che-
motherapy and complete remission rates vary between
70% and 80% [23-25]. Repeat dilatation and curettage is
generally avoided to prevent morbidity and mortality
caused by uterine perforation, haemorrhage, infection,
uterine adhesions, and anaesthetic complications [5].
The chemotherapy agents are administered until three
negative test results for b-hCG are achieved for three
consecutive weeks or until serious side effects develop
[12]. After the return to normal b-hCG levels two more
courses of chemotherapy can be given as consolidation
therapy [12]. Hysterectomy may play a role in the treat-
ment of GTN. First, it may be performed primarily to
treat placental site trophoblastic tumours, epithelioid
trophoblastic tumours, or chemotherapy-resistant dis-
ease. In addition, severe uncontrollable vaginal or intra-
abdominal bleeding may necessitate hysterectomy as an
emergency procedure [26].
Pulmonary metastases in most cases are treatable with
combined chemotherapy but sometimes it is necessary to
perform thoracotomy in order to remove a pulmonary
module that does not resolve after chemotherapy [12].
Brain metastases are treated by radiotherapy along with
chemotherapy. Chemotherapy alone can also be used for
brain disease [27]. The primary target of radiation is to
reduce the incidence of spontaneous intracranial bleeding
during or more commonly after chemotherapy [12,28].
Occasionally, craniotomy has to be performed in order to
decompress the brain after an acute cerebral haemor-
rhage [28]. Liver metastasis is managed with systemic
chemotherapy but intra-arterial chemoinfusion has been
tried as well [9]. Liver metastasis radiation can also be
applied [29]. It may sometimes be necessary to resect a
part of the liver in order to remove a persistent metasta-
sis or to control a haemorrhagic area [9].
Another treatment option is to start chemotherapy in
GTN with massive disease or metastatic sites likely
to bleed profusely (such as liver and brain) with a single
or double agent rather than multi-agent treatment
[1,2,18,19]. This can allow stabilization of the patient
and gradual response to the chemotherapy avoiding
rapid tumour necrosis which could lead to respiratory
function deterioration and excessive bleeding from
metastatic sites [1,2,18,19].
The presence of retroperitoneal diffuse metastases has
seldom been described and the clinician must be aware
of this extremely rare but fatal complication of meta-
static GTD since its course is initially insidious and can
rapidly lead to massive haemorrhage and death. The
presence of such metastases in our patient caused
massive bleeding after the completion of the first cycle
of chemotherapy rendering her haemodynamically
unstable. The fact that these metastases were diffuse
made it impossible for us to successfully control bleed-
ing during laparotomy and this had as a consequence
the disseminated intravascular coagulation of the
patient.
I nc o n c l u s i o ni ts e e m st h a tt h i sd e a t hw a sp r o b a b l y
was a failure of the diagnosis of retroperitoneal disease.
It therefore becomes obvious that better diagnostic,
treatment modalities and chemotherapeutic agents will
help to improve control of the disease and increase
patient survival. The gynaecologist should be aware of
all possible metastatic sites of GTN, moreover he should
be alert and capable of identifying this fatal complication
as soon as possible. In this case the patient should
immediately be referred to a specialist center for further
assessment and treatment.
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